Smith & Nephew has issued a safety notice, updating the indications for its Birmingham Hip Modular Head implants after data showed a 1.29 percent and 1.12 percent failure rate on two separate joint replacement registries in the U.K. and Australia, according to a
Mass Device report.
The failure rate exceeds the 1 percent benchmark set by the U.K.'s National Institute for Health and Clinical Excellence. As such, Smith & Nephew has updated the indications for the hip implants to restrict its use with the company's Synergy stems and during revision procedures. In these cases, the hip implant's failure rate drops to 1.07 percent, this is considered acceptable, according to the report.
The safety notice does not include a recall of any kind.
More Articles on Orthopedic Devices:
EOS imaging Announces First Installation in Asia
LDR Receives FDA Approval for Minimally Invasive Spinal Surgery Device
Curetis, Heraeus Medical Partner to Develop Test for Implant Infections 
